Predict your next investment

Family Office
bonitcapital.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

About Bonit Capital

Bonit Capital is a Swedish family office that invests across sectors and asset classes and looks for meaningful and entrepreneurial approaches to investing.

Bonit Capital Headquarter Location

Tandstickspalatset Vastra Tradgardsgatan 15

Stockholm, 111 53,

Sweden

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bonit Capital News

Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US.

Apr 6, 2022

News provided by Share this article Share this article STOCKHOLM, April 6, 2022 /PRNewswire/ -- Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led by European life science venture fund Hadean Ventures and joined by Scale Capital and Bonit Capital. Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies seeking to develop and launch DTx solutions. These digital health products are validated in clinical trials and prescribed by a doctor, similar to traditional therapeutics. This funding round will be used to accelerate Alex's growth in Europe and the US and to develop novel DTx products alongside both new and existing partners, including Pfizer. The round was led by Hadean Ventures, a European specialist life science venture fund, with participation from Scale Capital and Bonit Capital, the Leksell (founder of medical device company Elekta) family office. The new investors provide cross-disciplinary expertise in successfully developing medical devices and scaling global B2B tech platforms. Existing investors, the King (Candy Crush) founders through their fund Sweet Studio, also participated in the round. Alex Therapeutics uses its AI-powered digital therapeutics platform "Alex DTx Platform" to develop and launch prescription digital therapies, typically in partnership with pharmaceutical companies. The DTx products are clinically validated and approved medical devices, prescribed by doctors and reimbursed by healthcare systems. The platform combines evidence-based psychology, primarily Cognitive Behavioral Therapy (CBT), with AI and Machine Learning to provide personalized treatments that address the needs of patients worldwide. We're overwhelmed by the interest from the investor community and are glad to welcome some incredible institutional investors to join us as we take the next major leap with Alex. We're looking forward to learning from their many years of experience in developing medical devices and scaling Nordic tech platforms internationally. They perfectly complement our current investors, who have a unique perspective on building engaging consumer technology. John Drakenberg Renander, co-founder and CEO at Alex Therapeutics We've been following the digital therapeutics space for a long time and are now seeing major markets such as Germany and the US open up for prescription and reimbursement of digital therapies. Alex Therapeutics' impressive track record, dedication to developing treatments with and for patients, combined with their utilization of advanced technology make them an attractive partner for companies seeking to launch digital therapeutics. Dr. Ingrid Teigland Akay, MD, MBA, Managing Partner at Hadean Ventures Alex Therapeutics' journey has been incredible, and we're proud to have supported them from day one. Looking back, it's astonishing what John, Oliver and their team have accomplished in such a short period of time. With partners such as Pfizer, and now institutional investors with a strong track record in life science and international expansion, there's no limit to what they can do. Anders Frostenson, Founder & MD at Sweet Studio (King/Candy Crush founders fund) Announced strategic commercial partnership with Pfizer earlier this year Alex Therapeutics recently announced a strategic commercial partnership with the global pharmaceutical company Pfizer. The initial focus of the partnership is a digital therapy called Eila® treating nicotine addiction. About Alex Therapeutics Alex Therapeutics is a digital therapeutics (DTx) company based in Stockholm which designs and develops Software-as-a-Medical-Devices (SaMDs). With the proven "Alex DTx Platform", expertise in artificial intelligence and evidence-based psychology, Alex Therapeutics is uniquely positioned to deliver cutting-edge and reliable DTx products. The company has treated tens of thousands of patients, has experience with clinical validation, and overwhelmingly positive patient testimonials. For more information, visit www.alextherapeutics.com or follow us on LinkedIn . About Hadean Ventures Hadean Ventures is a European life science venture capital fund manager with c. €200m assets under management. Hadean Ventures has offices in Oslo, Norway, and Stockholm, Sweden, as well as a presence in Germany, Austria and the UK. Hadean invests across all healthcare verticals and stages with a focus on pharmaceuticals & biotech, medical devices, diagnostics and digital health. With a local European presence in regions that regularly produce world-class science, yet historically have been under-ventured, Hadean looks to find top opportunities with the flexibility to invest in great ideas no matter what vertical. For more information, please visit www.hadeanventures.com or follow us on LinkedIn . About Scale Capital Scale Capital is an early stage venture fund investing in digitization and disruptive technologies within business-to-business. Scale Capital primarily invests in companies in the Nordic region with the potential and ambition to win in the US market. We focus on delivering impact through technology that creates positive changes to the planet and people's lives. We are headquartered in Copenhagen and have offices in New York and Silicon Valley. About Bonit Capital Bonit Capital is a family-owned investment company within the life science and healthcare sector. Based in Stockholm, Bonit takes an active ownership approach by providing capital, industry expertise and access to an international network – focusing on the areas of digital health, medical technology, diagnostics and population health. For more information, please visit: https://bonitcapital.com This information was brought to you by Cision http://news.cision.com

Bonit Capital Investments

6 Investments

Bonit Capital has made 6 investments. Their latest investment was in Alex Therapeutics as part of their Series A on April 4, 2022.

CBI Logo

Bonit Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/6/2022

Series A

Alex Therapeutics

$3.82M

Yes

1

7/6/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/19/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

1/23/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/24/2019

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/6/2022

7/6/2021

7/19/2020

1/23/2020

4/24/2019

Round

Series A

Series A

Seed VC

Series B

Seed VC

Company

Alex Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.82M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Bonit Capital Portfolio Exits

1 Portfolio Exit

Bonit Capital has 1 portfolio exit. Their latest portfolio exit was ScientificMed on August 26, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/26/2021

Acquired

$99M

1

Date

8/26/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.